Babak Vakili, MD
Interventional Cardiology · Longwood, FLNPI 1407877384
Payments from drug & device makers
Across 359 payments — averaging $558.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$121K
- Esperion Therapeutics, Inc.$62K
- Johnson & Johnson$13K
- Abbott$2K
- Amgen$489
- Boston Scientific$351
- plus $2K from 21 others
What the payments were for
- Consulting fees$9,3605%
- Speaking & faculty fees$179,00989%
- Travel & lodging$4,7392%
- Food & beverage$7,0804%
- Education$220%
- Other$2680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 73 | $121,062 |
| Esperion Therapeutics, Inc. | 87 | $61,842 |
| Johnson & Johnson | 25 | $13,210 |
| Abbott | 71 | $1,761 |
| Amgen | 28 | $489 |
| Boston Scientific | 8 | $351 |
| Baxter Healthcare | 1 | $268 |
| Merck | 12 | $233 |
| Novartis | 11 | $198 |
| Bard Peripheral Vascular, Inc. | 4 | $190 |
| Medtronic(2 entities) | 4 | $188 |
| Philips North America LLC | 4 | $117 |
| Pfizer | 5 | $87 |
| Boehringer Ingelheim | 4 | $71 |
| Amarin Pharma, Inc. | 4 | $67 |
| Cashflow Solutions, LLC | 3 | $55 |
| Medicomp Inc | 2 | $46 |
| Lilly USA, LLC | 2 | $36 |
| Tactile Systems Technology Inc | 3 | $35 |
| Organogenesis Inc. | 1 | $35 |
| Cook Medical LLC | 1 | $23 |
| 180 Medical, Inc. | 1 | $22 |
| Siemens Medical Solutions USA, Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Bayer | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$80,111
- NEXLIZET$60,700
- NEXLETOL$60,700
- XARELTO$12,552
- RYBELSUS$8,606
- LITHOVUE EMPOWER$143
- Supera peripheral stent system$141
- Rotarex$120
- ClosureFast$114
How this compares
$200,477 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $169,941 |
| XareltoRivaroxaban | 67 | $81,701 |
| JardianceEmpagliflozin | 31 | $46,417 |
| EntrestoSacubitril/Valsartan | 18 | $32,629 |
| Repatha SureclickEvolocumab | 27 | $28,621 |
| BrilintaTicagrelor | 20 | $18,013 |
| Repatha SyringeEvolocumab | 11 | $17,975 |
| NexletolBempedoic Acid | 21 | $16,828 |
| OzempicSemaglutide | 15 | $14,059 |
| Rosuvastatin Calcium | 132 | $1,863 |
| Ezetimibe | 86 | $1,805 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 54 | $1,633 |
| Losartan Potassium | 161 | $1,394 |
| ClopidogrelClopidogrel Bisulfate | 95 | $1,168 |
| Atorvastatin Calcium | 130 | $1,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $87 | $169,941137 claims |
| Johnson & JohnsonXarelto | $13,210 | $81,70167 claims |
| Boehringer IngelheimJardiance | $71 | $46,41731 claims |
| NovartisEntresto | $198 | $32,62918 claims |
| AstraZenecaBrilinta | $20 | $18,01320 claims |
| Esperion Therapeutics, Inc.Nexletol | $61,842 | $16,82821 claims |
| Novo NordiskOzempic | $121,062 | $14,05915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Longwood
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.